MDT

95.75

-0.44%↓

VEEV

295.35

+2.17%↑

142.7

+2.53%↑

HQY

92.05

-3.24%↓

TLRY

1.63

0%↓

MDT

95.75

-0.44%↓

VEEV

295.35

+2.17%↑

142.7

+2.53%↑

HQY

92.05

-3.24%↓

TLRY

1.63

0%↓

MDT

95.75

-0.44%↓

VEEV

295.35

+2.17%↑

142.7

+2.53%↑

HQY

92.05

-3.24%↓

TLRY

1.63

0%↓

MDT

95.75

-0.44%↓

VEEV

295.35

+2.17%↑

142.7

+2.53%↑

HQY

92.05

-3.24%↓

TLRY

1.63

0%↓

MDT

95.75

-0.44%↓

VEEV

295.35

+2.17%↑

142.7

+2.53%↑

HQY

92.05

-3.24%↓

TLRY

1.63

0%↓

Inicio・Lista de Acciones・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Cerrado

SectorSalud

15.08 -1.24

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

Máximo

15.79

Métricas clave
By Trading Economics
Ingresos	13M -72M
Ventas	18M 38M
Margen de beneficio	-189.28
Empleados	270
EBITDA	20M -64M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+117.7% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 nov 2025

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	520M 1.4B
Apertura anterior	16.32
Cierre anterior	15.08

Noticias sobre sentimiento de mercado

By Acuity

50%

166 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

9.91 / 14.15 Soporte y Resistencia

Syndax Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

14 oct 2025, 22:33 UTC

Ganancias

America Movil 3Q Profit Jumps on Higher Revenue, Lower Financial Costs

14 oct 2025, 22:21 UTC

Principales Movimientos del Mercado

Dentsply Sirona Shares Rise After SEC Probe Ends

14 oct 2025, 19:27 UTC

Adquisiciones, fusiones, absorciones

Bouygues Telecom, Free-iliad, Orange Offer to Buy Most Altice French Assets for About $20 Billion

14 oct 2025, 17:56 UTC

Principales Movimientos del Mercado

Nova Minerals Surges; Will Provide Minerals Briefing to Australian Government Ahead of Trump Meeting

14 oct 2025, 23:38 UTC

Charlas de Mercado

Nikkei May Rise Amid Possible Bargain-Hunting -- Market Talk

14 oct 2025, 22:12 UTC

Charlas de Mercado

Ganancias

Fletcher Building's 1H Earnings Likely Down 16% -- Market Talk

14 oct 2025, 21:40 UTC

Ganancias

America Movil 3Q EBITDA MXN93.82B, Up 4.9% on Year >AMX.MX

14 oct 2025, 21:39 UTC

Ganancias

America Movil 3Q Rev MXN232.92B, Up 4.2% on Year >AMX.MX

14 oct 2025, 21:38 UTC

Ganancias

America Movil 3Q Net MXN22.7B Vs. Net MXN6.43B Year Ago >AMX.MX

14 oct 2025, 21:06 UTC

Ganancias

These Stocks Moved the Most Today: JPMorgan, Wells Fargo, Goldman, AMD, Walmart, J&J, Navitas, Polaris, and More -- Barrons.com

14 oct 2025, 20:50 UTC

Charlas de Mercado

Ganancias

Financial Services Roundup: Market Talk

14 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

14 oct 2025, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

14 oct 2025, 20:50 UTC

Charlas de Mercado

Ganancias

Health Care Roundup: Market Talk

14 oct 2025, 20:13 UTC

Ganancias

BlackRock's Assets Hit Record $13.5 Trillion After Market Rally, Dealmaking Spree -- 2nd Update

14 oct 2025, 20:01 UTC

Ganancias

Goldman Sachs Profit Surges, Fueled by Dealmaking Boom -- 5th Update

14 oct 2025, 19:21 UTC

Charlas de Mercado

Ganancias

Citigroup's Higher Outlook Leaves Questions -- Market Talk

14 oct 2025, 19:12 UTC

Adquisiciones, fusiones, absorciones

Bouygues Telecom, Free-iliad, Orange Offer to Buy Most Altice French Assets for About $20B

14 oct 2025, 19:08 UTC

Charlas de Mercado

Oil Futures Settle Lower on Trade, Oversupply Concerns -- Market Talk

14 oct 2025, 19:02 UTC

Charlas de Mercado

U.S. Natural Gas Falls as Weather Outlook Stays Mild -- Market Talk

14 oct 2025, 18:59 UTC

Adquisiciones, fusiones, absorciones

Bouygues Telecom, Free-iliad Group, Orange Bid for Corresponds to Total Enterprise Value of EUR17B for Altice France Assets

14 oct 2025, 18:58 UTC

Adquisiciones, fusiones, absorciones

Bouygues Telecom, Free-iliad Group, Orange Bid Excludes Stakes in Intelcia, UltraEdge, XP Fibre, Altice Technical Services

14 oct 2025, 18:58 UTC

Adquisiciones, fusiones, absorciones

Bouygues Telecom, Free-iliad Group, Orange Bid Covers Most SFR Assets

14 oct 2025, 18:56 UTC

Adquisiciones, fusiones, absorciones

Bouygues Telecom, Free-iliad Group, Orange Submit Joint Non-Binding Offer to Buy Large Part of Altice's Activities in France

14 oct 2025, 18:46 UTC

Ganancias

These Stocks Are Moving the Most Today: JPMorgan, Wells Fargo, Goldman, AMD, Walmart, J&J, Navitas, Polaris, and More -- Barrons.com

14 oct 2025, 18:04 UTC

Ganancias

Goldman Sachs Profit Surges, Fueled by Dealmaking Boom -- 4th Update

14 oct 2025, 18:01 UTC

Charlas de Mercado

Gold Finds Another Record as Traders Eye Further Upside -- Market Talk

14 oct 2025, 17:54 UTC

Ganancias

Salesforce's Dreamforce Conference Kicks Off. CEO Benioff Touts AI Tool Agentforce. -- Barrons.com

14 oct 2025, 17:50 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

14 oct 2025, 17:50 UTC

Charlas de Mercado

Lower Dollar Provides Some Strength in Grains -- Market Talk

Comparación entre iguales

Cambio de precio

Syndax Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

117.7% repunte

Estimación a 12 meses

Media 33.33 USD 117.7%

Máximo 56 USD

Mínimo 17 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Syndax Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

11 ratings

Comprar

Mantener

Vender

De acuerdo con 11 analistas que ofrecen calificaciones bursátiles a para Syndax Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

9.91 / 14.15Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentimiento

By Acuity

166 / 371 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.